Citius Oncology Launches LYMPHIR™ Cancer Immunotherapy with Market Potential Exceeding $400 Million
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 23 2025
0mins
Source: PRnewswire
- Product Launch: Citius Oncology launched LYMPHIR™ in December 2025 in the U.S., marking the first new systemic therapy for cutaneous T-cell lymphoma since 2018, which signifies a major advancement in the company's oncology treatment portfolio.
- Market Opportunity: Management estimates that the initial market for LYMPHIR™ exceeds $400 million and is growing, indicating a significant commercial opportunity for Citius as existing therapies fail to meet patient needs.
- Intellectual Property Protection: LYMPHIR™ is supported by robust intellectual property protections, including orphan drug designation and pending patents, which will further enhance Citius's competitive positioning in the oncology treatment landscape.
- Future Development Plans: Citius is actively engaging with the FDA to advance Mino-Lok and explore additional indications and markets for LYMPHIR™, demonstrating the company's commitment to sustained growth and innovation.
Analyst Views on CTXR
About CTXR
Citius Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of first-in-class critical care products, with a pipeline of anti-infectives in oncology, adjunct cancer care, stem cell therapy and prescription products. The Company's FDA approved LYMPHIR candidate is a targeted immunotherapy for an initial indication in the treatment of cutaneous T-cell lymphoma. Its late-stage pipeline also includes Mino-Lok, and CITI-002 (Halo-Lido). Mino-Lok is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections (CRBSIs) and central line associated bloodstream infections (CLABSIs). Halo-Lido is a topical formulation of halobetasol propionate, a corticosteroid, and lidocaine that is intended for the treatment of hemorrhoids. The Company is also seeking to develop and commercialize the NoveCite mesenchymal stem cells (NC-iMSCs) to treat acute respiratory conditions with a near term focus on ARDS.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
